"interventions","locations","postcode","nct_id","brief_title","overall_status","condition","site_name","site_status","investigators","contacts","Refresh.date","matching.condition","TARGET.condition","Link","postcode.lat","postcode.long","lat","long","ParentTerm"
"PF-06801591","London","EC1A 7BE","NCT04165317","Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer","Recruiting","Non-muscle Invasive Bladder Cancer","Barts Health NHS Trust, St Bartholomew's Hospital","Recruiting",NA,NA,"08 April 2021","bladder cancer","Bladder","https://clinicaltrials.gov/ct2/show/NCT04165317",51.51775,-0.100404,51.51775,-0.100404,"PD1 Inhibitor"
"PF-06801591","London","W6 8RF","NCT04165317","Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer","Recruiting","Non-muscle Invasive Bladder Cancer","Charing Cross Hospital","Not yet recruiting",NA,NA,"08 April 2021","bladder cancer","Urological","https://clinicaltrials.gov/ct2/show/NCT04165317",51.487045,-0.219935,51.487045,-0.219935,"PD1 Inhibitor"
"PF-06801591","London","W6 8RF","NCT04165317","Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer","Recruiting","Non-muscle Invasive Bladder Cancer","Charing Cross Hospital","Not yet recruiting",NA,NA,"08 April 2021","bladder cancer","Bladder","https://clinicaltrials.gov/ct2/show/NCT04165317",51.487045,-0.219935,51.487045,-0.219935,"PD1 Inhibitor"
"PF-06801591","London","EC1A 7BE","NCT04165317","Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer","Recruiting","Non-muscle Invasive Bladder Cancer","Barts Health NHS Trust, St Bartholomew's Hospital","Recruiting",NA,NA,"08 April 2021","bladder cancer","Urological","https://clinicaltrials.gov/ct2/show/NCT04165317",51.51775,-0.100404,51.51775,-0.100404,"PD1 Inhibitor"
